Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol

Authors:

Abstract
With the future advent of a world wide ban on chlorofluorocarbon containing aerosols, a study was designed to compare the in vivo lung bioavailability of salbutamol via chlorofluorocarbon‐containing metered‐dose inhaler (CFC), chlorofluorocarbon‐free metered‐dose inhaler (CFC‐free), and dry powder inhaler (DPI). Twelve healthy male subjects were given 1200 μg salbutamol and measurements made of plasma and urinary salbutamol. CFC‐free produced significantly higher plasma salbutamol levels (ng ml‐1; mean and 95% CI for difference) than either CFC or DPI: Cmax, CFC‐free 4.18 vs CFC 3.29 (95% CI 0.10–1.68), vs DPI 3.42 (95% CI ‐0.03–1.56). The ratio for the difference in Cmax between CFC and CFC‐free formulations was 1.32 (95% CI 1.02–1.61). There were no significant differences between CFC and DPI formulations. Urinary salbutamol results did not reveal any significant differences between the three inhalers (μg 30 min‐1): CFC‐free 42.4, CFC 43.8, DPI 45.3. Thus, the lung bioavailibility of CFC‐free was greater than that of CFC or DPI formulations of salbutamol.

This publication has 7 references indexed in Scilit: